After Malaysian healthcare giant IHH's $1.3bn buy-out of controversy-riddled Fortis Healthcare, the Indian hospital group's diagnostic lab SRL has launched a major push to improve its dwindling sales. Is it worth trying to impress incoming management, or will Fortis drop the business? We speak to an analyst to find out more.



